EMD Serono's shocking leadership change: Miguel Fernández Alcalde becomes president

In a strategic move to enhance its standing in the critical U.S. healthcare market, EMD Serono, which operates as the healthcare branch of Merck KGaA, Darmstadt, Germany, appointed Miguel Fernández Alcalde as its new President. This transition follows the retirement of Chris Round, who held the position for over three years after a lengthy and diverse career with the company. During his tenure, Round was pivotal in guiding the organization through numerous successful product launches, robust growth, and the development of a strong talent pool. His departure signals a significant shift in leadership as the company looks to continue its upward trajectory in the rapidly evolving biopharmaceutical landscape of the United States. Peter Guenter, a member of Merck KGaA's Executive Board and CEO of Healthcare, commended Fernández Alcalde's extensive experience, remarking that his leadership is crucial for navigating the challenges ahead in this essential market. Fernández Alcalde, who had served as Chief Operating Officer for EMD Serono before his new appointment, expressed his commitment to addressing the unmet medical needs of patients and building on the foundation laid by his predecessor. His career with Merck KGaA began in 2014, and he has held several key roles, including managing General Operations in different countries, showcasing his capability and readiness for this prominent leadership role. With a focus on improving patient outcomes, Fernández Alcalde aims to spearhead initiatives that align with the company's global healthcare strategy while ensuring that EMD Serono retains its competitive edge in the sector. It is expected that under his stewardship, the company will continue innovating and growing in the U.S biopharmaceutical industry.